Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing POAI’s motivations and operations, “an estimated 21,750 women received a new diagnosis of ovarian cancer this year (2020), and almost 14,000 women will die from the disease. Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women.” In a bid to change this reality, Predictive Oncology, a company that focuses on using data and artificial intelligence to develop personalized cancer therapies, has partnered with the University of Pittsburg School of Medicine, through Helomics, “to study the use of artificial intelligence (‘AI’) to improve clinical decision making for ovarian cancer patients. The collaboration entails using Helomics’ AI platform and proprietary data to analyze the genomic and drug response profiles of women with ovarian cancer to evaluate predictive values in terms of response and non-response to different treatments… Helomics’ predictive models will save time and money in the search for new targeted therapies.”
To view the full article, visit https://ibn.fm/XFUqG
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.